通过有效地产生大规模的TCR-T细胞来增强抗瘤反应,这些细胞针对多个癌症抗原中的单个表位向单个表位
Obed Boadi Amissah1, Rajesh Basnet1, Wenfang Chen1
1CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Shijingshan District, Beijing 100049, China.
Cellular immunology
|May 11, 2024
概括
这项研究开发了一种高效的方法,用于大规模的T细胞受体 (TCR) -T细胞扩张,使用Xeno/Sera-free介质. 针对CTAG1和CTAG2抗原的共同表位增强了抗癌活性,提高了采用细胞治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞生物学 细胞生物学
背景情况:
- 收养细胞疗法面临着大规模生产和高成本的挑战.
- 表达CTAG1和CTAG2抗原的癌症类型提供了潜在的标,因为它们具有共同的表位.
- 改善T细胞受体 (TCR) -T细胞疗法需要高效的产生和增强的抗瘤反应.
研究的目的:
- 开发一种用于大规模,高质量的TCR-T细胞生成的高效方法.
- 调查针对CTAG1和CTAG2抗原的共同表位的潜力,以改善癌症治疗.
- 评估不同的培养条件和T-激活器刺激方法,用于TCR-T细胞扩张和功能.
主要方法:
- 使用异种/无血清介质和人类AB血清扩张TCR-T细胞.
- 珠子涂层T-激活剂与可溶性T-激活剂用于TCR-T细胞刺激的比较.
- 对增强抗瘤活性的双抗原-表位向 (CTAG1/CTAG2) 的评估.
主要成果:
- 无/无介质使TCR-T细胞扩张超过500倍,性能优于FBS补充介质.
- 与可溶性T-激活剂相比,珠涂T-激活剂刺激导致了优异的TCR-T细胞效应器功能.
- 针对具有共同表位的多个抗原的TCR-T细胞表现出比单抗原向更高的抗癌活性.
结论:
- 高效,大规模的TCR-T细胞生产是可以利用无异种/无血清介质实现的,从而降低成本.
- 针对CTAG1和CTAG2的双抗原-表位向提供了一种有前途的策略,以提高TCR-T细胞治疗的疗效.
- 优化的T细胞扩张和刺激方法对于改善采用细胞疗法的临床成功至关重要.
相关概念视频
Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cytotoxic T Cells-mediated Immune Response
901
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
901
T Cell Activation and Clonal Selection
709
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
709


